PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer

The blockade of immune checkpoints in cancer immunotherapy

Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838

Safety, activity, and immune correlates of anti–PD-1 antibody in cancer

Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628

Comprehensive molecular portraits of human breast tumours

The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129

Safety and activity of anti-PD-L1 antibody in patients with advanced cancer

Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945

Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer

Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

Herbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198

Pembrolizumab versus Ipilimumab in Advanced Melanoma

Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887

Nivolumab in Previously Untreated Melanoma without BRAF Mutation

Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231

Genetic Engineering of Immune Evasive Stem Cell-Derived Islets

Sackett, S. D., Kaplan, S. J., Mitchell, S. A., Brown, M. E., Burrack, A. L., Grey, S., Huangfu, D., & Odorico, J. (2022) · Transplant International · doi:10.3389/ti.2022.10817 · Cited by 32

Helicobacter pylori serology is associated with worse overall survival in patients with melanoma treated with immune checkpoint inhibitors

Tonneau, M., Nolin-Lapalme, A., Kazandjian, S., Auclin, E., Panasci, J., Benlaifaoui, M., Ponce, M., Al-Saleh, A., Belkaid, W., Naimi, S., et al. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2096535 · Cited by 34

5T4 oncofoetal glycoprotein: an old target for a novel prostate cancer immunotherapy

Cappuccini, F., Pollock, E., Stribbling, S., Hill, A. V. S., & Redchenko, I. (2017) · Oncotarget · doi:10.18632/oncotarget.17666 · Cited by 31

Heat Shock Protein 90 Family Isoforms as Prognostic Biomarkers and Their Correlations with Immune Infiltration in Breast Cancer

Lin, T., Qiu, Y., Peng, W., & Peng, L. (2020) · BioMed Research International · doi:10.1155/2020/2148253 · Cited by 31

Proteomic test for anti-PD-1 checkpoint blockade treatment of metastatic melanoma with and without BRAF mutations

Ascierto, P. A., Capone, M., Grimaldi, A. M., Mallardo, D., Simeone, E., Madonna, G., Roder, H., Meyer, K., Asmellash, S., Oliveira, C., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0569-1 · Cited by 30

Targeting eIF4A triggers an interferon response to synergize with chemotherapy and suppress triple-negative breast cancer

Zhao, N., Kabotyanski, E. B., Saltzman, A. B., Malovannaya, A., Yuan, X., Reineke, L. C., Lieu, N., Gao, Y., Pedroza, D. A., Calderon, S. J., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci172503 · Cited by 30

Molecular determinants of drug-specific sensitivity for epidermal growth factor receptor (EGFR) exon 19 and 20 mutants in non-small cell lung cancer

Tsigelny, I. F., Wheler, J. J., Greenberg, J. P., Kouznetsova, V. L., Stewart, D. J., Bazhenova, L., & Kurzrock, R. (2015) · Oncotarget · doi:10.18632/oncotarget.3472 · Cited by 30

Murine fecal microbiota transfer models selectively colonize human microbes and reveal transcriptional programs associated with response to neoadjuvant checkpoint inhibitors

Shaikh, F. Y., Gills, J. J., Mohammad, F., White, J. R., Stevens, C. M., Ding, H., Fu, J., Tam, A., Blosser, R. L., Domingue, J. C., et al. (2022) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-022-03169-6 · Cited by 30

Generation of peptides using phage display technology for cancer diagnosis and molecular imaging

Pung, H. S., Tye, G. J., Leow, C. H., Ng, W. K., & Lai, N. S. (2023) · Molecular Biology Reports · doi:10.1007/s11033-023-08380-x · Cited by 30

Genetic and epigenetic analysis of the beta-2-microglobulin gene in microsatellite instable colorectal cancer

Snahnicanova, Z., Kasubova, I., Kalman, M., Grendar, M., Mikolajcik, P., Gabonova, E., Laca, L., Caprnda, M., Rodrigo, L., Ciccocioppo, R., et al. (2020) · Clinical and Experimental Medicine · doi:10.1007/s10238-019-00601-7 · Cited by 29

The impact of immunosenescence on the efficacy of immune checkpoint inhibitors in melanoma patients: a meta-analysis

Li, P., Yang, X., Feng, Y., Wu, L., Ma, W., Ding, G., Wei, Y., & Sun, L. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s165368 · Cited by 29

CD8-positive T cells and CD204-positive M2-like macrophages predict postoperative prognosis of very high-risk prostate cancer

Yanai, Y., Kosaka, T., Mikami, S., Hongo, H., Yasumizu, Y., Takeda, T., Matsumoto, K., Miyauchi, J., Kitano, S., & Oya, M. (2021) · Scientific Reports · doi:10.1038/s41598-021-01900-4 · Cited by 28

Potential Risk Factors for Nivolumab-induced Thyroid Dysfunction

(2017) · In Vivo · doi:10.21873/invivo.11195 · Cited by 28

A novel gammaretroviral shuttle vector insertional mutagenesis screen identifies SHARPIN as a breast cancer metastasis gene and prognostic biomarker

Bii, V. M., Rae, D. T., & Trobridge, G. D. (2015) · Oncotarget · doi:10.18632/oncotarget.6232 · Cited by 28

A transcriptome-based human universal senescence index (hUSI) robustly predicts cellular senescence under various conditions

Wang, J., Zhou, X., Yu, P., Yao, J., Guo, P., Xu, Q., Zhao, Y., Wang, G., Li, Q., Zhu, X., et al. (2025) · Nature Aging · doi:10.1038/s43587-025-00886-2 · Cited by 28

Fusobacterium nucleatum carcinogenesis and drug delivery interventions

Chen, Z., & Huang, L. (2024) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2024.115319 · Cited by 27

Obesity and Cancer Immunotherapy Toxicity

Mirsoian, A., & Murphy, W. J. (2015) · Immunotherapy · doi:10.2217/imt.15.12 · Cited by 26

Strategies for Small Extracellular Vesicle-Based Cancer Immunotherapy

Chen, Y., Tang, S., Cai, F., & Wan, Y. (2024) · Research · doi:10.34133/research.0421 · Cited by 26

Intermittent hypoxia enhances the tumor programmed death ligand 1 expression in a mouse model of sleep apnea

Huang, M.-H., Zhang, X.-B., Wang, H.-L., Li, L.-X., Zeng, Y.-M., Wang, M., & Zeng, H.-Q. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2019.01.44 · Cited by 25

Neoadjuvant In Situ Immunomodulation Enhances Systemic Antitumor Immunity against Highly Metastatic Tumors

Oba, T., Kajihara, R., Yokoi, T., Repasky, E. A., & Ito, F. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-0939 · Cited by 26

Incidence of Thyroid Function Test Abnormalities in Patients Receiving Immune-Checkpoint Inhibitors for Cancer Treatment

Patel, N. S., Oury, A., Daniels, G. A., Bazhenova, L., & Patel, S. P. (2018) · The Oncologist · doi:10.1634/theoncologist.2017-0375 · Cited by 25

Complete regression of cutaneous metastases with systemic immune response in a patient with triple negative breast cancer receiving p53MVA vaccine with pembrolizumab

Yuan, Y., Kos, F. J., He, T.-F., Yin, H. H., Li, M., Hardwick, N., Zurcher, K., Schmolze, D., Lee, P., Pillai, R. K., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1363138 · Cited by 23

Effect of cyclical intermittent hypoxia on Ad5CMVCre induced solitary lung cancer progression and spontaneous metastases in the KrasG12D+; p53fl/fl; myristolated p110fl/fl ROSA-gfp mouse

Guo, X., Liu, Y., Kim, J. L., Kim, E. Y., Kim, E. Q., Jansen, A., Li, K., Chan, M., Keenan, B. T., Conejo-Garcia, J., et al. (2019) · PLOS ONE · doi:10.1371/journal.pone.0212930 · Cited by 23

Correlation between thyroid transcription factor-1 expression, immune-related thyroid dysfunction, and efficacy of anti-programmed cell death protein-1 treatment in non-small cell lung cancer

Koyama, J., Horiike, A., Yoshizawa, T., Dotsu, Y., Ariyasu, R., Saiki, M., Sonoda, T., Uchibori, K., Nishikawa, S., Kitazono, S., et al. (2019) · Journal of Thoracic Disease · doi:10.21037/jtd.2019.04.102 · Cited by 23

A Paradoxical Role for Regulatory T Cells in the Tumor Microenvironment of Pancreatic Cancer

Brouwer, T., Ijsselsteijn, M., Oosting, J., Ruano, D., van der Ploeg, M., Dijk, F., Bonsing, B., Fariña, A., Morreau, H., Vahrmeijer, A., et al. (2022) · Cancers · doi:10.3390/cancers14163862 · Cited by 24

Novel Therapies in Platinum-refractory Metastatic Germ Cell Tumor: A Case Report with a Focus on a PD-1 Inhibitor

Loh, K. P., & Fung, C. (2017) · Rare Tumors · doi:10.4081/rt.2017.6867 · Cited by 23

Comprehensive analysis of DNA damage repair deficiency in 10,284 pan–cancer study

Xiao, Y., Lu, D., Lei, M., Xie, W., Chen, Y., Zheng, Y., Wang, C., Zhao, J., Zhu, Z., Zhao, X., et al. (2021) · Annals of Translational Medicine · doi:10.21037/atm-21-5449 · Cited by 22

Induction of T-Cell Infiltration and Programmed Death Ligand 2 Expression by Adeno-Associated Virus in Rhesus Macaque Skeletal Muscle and Modulation by Prednisone

Cramer, M. L., Shao, G., Rodino-Klapac, L. R., Chicoine, L. G., & Martin, P. T. (2017) · Human Gene Therapy · doi:10.1089/hum.2016.113 · Cited by 22

Systemic Inflammation/Nutritional Status Scores Are Prognostic but Not Predictive in Metastatic Non-Small-Cell Lung Cancer Treated with First-Line Immune Checkpoint Inhibitors

Mahiat, C., Bihin, B., Duplaquet, F., Stanciu Pop, C., Dupont, M., Vander Borght, T., Rondelet, B., Vanderick, J., André, B., Pirard, L., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043618 · Cited by 23

Two Distinct Myeloid Subsets at the Term Human Fetal-Maternal Interface

Costa, M. L., Robinette, M. L., Bugatti, M., Longtine, M. S., Colvin, B. N., Lantelme, E., Vermi, W., Colonna, M., Nelson, D. M., & Cella, M. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01357 · Cited by 22

Treatment Options for EGFR T790M-Negative EGFR Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer

Corallo, S., D’Argento, E., Strippoli, A., Basso, M., Monterisi, S., Rossi, S., Cassano, A., & Barone, C. M. (2017) · Targeted Oncology · doi:10.1007/s11523-017-0479-4 · Cited by 22

The somatic molecular evolution of cancer: Mutation, selection, and epistasis

Dasari, K., Somarelli, J. A., Kumar, S., & Townsend, J. P. (2021) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2021.08.003 · Cited by 22

The status of immunosuppression in patients with stage IIIB or IV non-small-cell lung cancer correlates with the clinical characteristics and response to chemotherapy

Wang, Y., Hu, G.-F., & Wang, Z. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s136259 · Cited by 21

HER3 Alterations in Cancer and Potential Clinical Implications

Kilroy, M. K., Park, S., Feroz, W., Patel, H., Mishra, R., Alanazi, S., & Garrett, J. T. (2022) · Cancers · doi:10.3390/cancers14246174 · Cited by 21

Combining texture features of whole slide images improves prognostic prediction of recurrence-free survival for cutaneous melanoma patients

Peng, Y., Chu, Y., Chen, Z., Zhou, W., Wan, S., Xiao, Y., Zhang, Y., & Li, J. (2020) · World Journal of Surgical Oncology · doi:10.1186/s12957-020-01909-5 · Cited by 21

Impact of bowel movement condition on immune checkpoint inhibitor efficacy in patients with advanced non‐small cell lung cancer

Katayama, Y., Yamada, T., Tanimura, K., Yoshimura, A., Takeda, T., Chihara, Y., Tamiya, N., Kaneko, Y., Uchino, J., & Takayama, K. (2019) · Thoracic Cancer · doi:10.1111/1759-7714.12969 · Cited by 20

Acral melanoma in skin of color: current insights and future directions: a narrative review

Nadelmann, E., Singh, A., Abbruzzese, M., Adeuyan, O., Kenchappa, D., Kovrizhkin, K., Lightman, M., Samouha, A., Tao, K., Yun, J., et al. (2025) · Cancers · doi:10.3390/cancers17030468 · Cited by 20

Evolution of chromosome-arm aberrations in breast cancer through genetic network rewiring

Kuzmin, E., Baker, T. M., Lesluyes, T., Monlong, J., Abe, K. T., Coelho, P. P., Schwartz, M., Del Corpo, J., Zou, D., Morin, G., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.113988 · Cited by 20

Bidimensional linked matrix factorization for pan-omics pan-cancer analysis

Lock, E. F., Park, J. Y., & Hoadley, K. A. (2022) · The Annals of Applied Statistics · doi:10.1214/21-aoas1495 · Cited by 19

Breakthroughs in the treatment of advanced squamous-cell NSCLC: not the neglected sibling anymore?

Tsironis, G., Ziogas, D. C., Kyriazoglou, A., Lykka, M., Koutsoukos, K., Bamias, A., & Dimopoulos, M.-A. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2018.02.18 · Cited by 19

Deep proteomic analysis on biobanked paraffine-archived melanoma with prognostic/predictive biomarker read-out

Szadai, L., Velasquez, E., Szeitz, B., Almeida, N. P. D., Domont, G., Betancourt, L. H., Gil, J., Marko-Varga, M., Oskolas, H., Jánosi, Á. J., et al. (2021) · Cancers · doi:10.3390/cancers13236105 · Cited by 18

Impact of Diets on Response to Immune Checkpoint Inhibitors (ICIs) Therapy against Tumors

Zhang, X., Li, H., Lv, X., Hu, L., Li, W., Zi, M., & He, Y. (2022) · Life · doi:10.3390/life12030409 · Cited by 18

Pleiotropy-guided transcriptome imputation from normal and tumor tissues identifies candidate susceptibility genes for breast and ovarian cancer

Kar, S. P., Considine, D. P. C., Tyrer, J. P., Plummer, J. T., Chen, S., Dezem, F. S., Barbeira, A. N., Rajagopal, P. S., Rosenow, W. T., Moreno, F., et al. (2021) · Human Genetics and Genomics Advances · doi:10.1016/j.xhgg.2021.100042 · Cited by 18

Murine MHC-Deficient Nonobese Diabetic Mice Carrying Human HLA-DQ8 Develop Severe Myocarditis and Myositis in Response to Anti–PD-1 Immune Checkpoint Inhibitor Cancer Therapy

Racine, J. J., Bachman, J. F., Zhang, J.-G., Misherghi, A., Khadour, R., Kaisar, S., Bedard, O., Jenkins, C., Abbott, A., Forte, E., et al. (2024) · The Journal of Immunology · doi:10.4049/jimmunol.2300841 · Cited by 17

Development and Validation of a Robust Immune-Related Prognostic Signature for Gastric Cancer

Huo, J., Wu, L., & Zang, Y. (2021) · Journal of Immunology Research · doi:10.1155/2021/5554342 · Cited by 16

Immunological mechanisms underlying clinical phenotypes and noninvasive diagnosis of immune checkpoint inhibitor-induced kidney disease

Seethapathy, H., Mistry, K., & Sise, M. E. (2023) · Immunological Reviews · doi:10.1111/imr.13243 · Cited by 15

The PP2A-B56 phosphatase opposes cyclin E autocatalytic degradation via site-specific dephosphorylation

Davis, R. J., Swanger, J., Hughes, B. T., & Clurman, B. E. (2017) · Molecular and Cellular Biology · doi:10.1128/mcb.00657-16 · Cited by 15

Gut microbiota diversity and composition in predicting immunotherapy response and immunotherapy-related colitis in melanoma patients: A systematic review

Oey, O., Liu, Y.-Y., Sunjaya, A. F., Simadibrata, D. M., Khattak, M. A., & Gray, E. (2022) · World Journal of Clinical Oncology · doi:10.5306/wjco.v13.i11.929 · Cited by 15

Deep learning analysis of histopathological images predicts immunotherapy prognosis and reveals tumour microenvironment features in non-small cell lung cancer

Wang, Y., Ju, X., Hua, R., Chen, J., Dai, X., Liu, L., Wang, G., Bai, Y., Hu, H., & Li, X. (2024) · British Journal of Cancer · doi:10.1038/s41416-024-02856-8 · Cited by 18

Radiosensitizing effect of a novel CTSS inhibitor by enhancing BRCA1 protein stability in triple‐negative breast cancer cells

Choi, E., Jeon, K., Lee, H., Mun, G., Kim, J., Shin, J., Kwon, Y., Na, Y., & Lee, Y. (2024) · Cancer Science · doi:10.1111/cas.16174 · Cited by 15

Neoadjuvant immune checkpoint inhibition in the management of glioblastoma: Exploring a new frontier

Frederico, S. C., Darling, C., Bielanin, J. P., Dubinsky, A. C., Zhang, X., Hadjipanayis, C. G., & Kohanbash, G. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1057567 · Cited by 15

PTEN is required to maintain luminal epithelial homeostasis and integrity in the adult mammary gland

Shore, A. N., Chang, C.-H., Kwon, O.-J., Weston, M. C., Zhang, M., Xin, L., & Rosen, J. M. (2016) · Developmental Biology · doi:10.1016/j.ydbio.2015.10.023 · Cited by 15

A Chemical Approach to Assess the Impact of Post-translational Modification on MHC Peptide Binding and Effector Cell Engagement

Kelly, J. J., Bloodworth, N., Shao, Q., Shabanowitz, J., Hunt, D., Meiler, J., & Pires, M. M. (2024) · ACS Chemical Biology · doi:10.1021/acschembio.4c00312 · Cited by 15

Real-world analyses of therapy discontinuation of checkpoint inhibitors in metastatic melanoma patients

Machado, M. A. D. Á., de Moura, C. S., Chan, K., Curtis, J. R., Hudson, M., Abrahamowicz, M., Jamal, R., Pilote, L., & Bernatsky, S. (2020) · Scientific Reports · doi:10.1038/s41598-020-71788-z · Cited by 14

Advances in adoptive cellular therapy for colorectal cancer: A narrative review

Yi, X., & Hu, W. (2022) · Annals of Translational Medicine · doi:10.21037/atm-22-6196 · Cited by 14

On the inconsistency of ℓ 1-penalised sparse precision matrix estimation

Heinävaara, O., Leppä-aho, J., Corander, J., & Honkela, A. (2016) · BMC Bioinformatics · doi:10.1186/s12859-016-1309-x · Cited by 14

Facts and Hopes in Immunotherapy Strategies Targeting Antigens Derived from KRAS Mutations

Linette, G. P., Bear, A. S., & Carreno, B. M. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-1212 · Cited by 14

Stimulation of natural killer cells with rhCD137 ligand enhances tumor-targeting antibody efficacy in gastric cancer

Misumi, T., Tanabe, K., Fujikuni, N., & Ohdan, H. (2018) · PLoS ONE · doi:10.1371/journal.pone.0204880 · Cited by 12

Associations between HIFs and tumor immune checkpoints: mechanism and therapy

Liu, J., Jiang, Y., Chen, L., Qian, Z., & Zhang, Y. (2024) · Discover Oncology · doi:10.1007/s12672-023-00836-7 · Cited by 13

Microphysiological systems as models for immunologically ‘cold’ tumors

Gaebler, D., Hachey, S. J., & Hughes, C. C. W. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1389012 · Cited by 14

H2AX mRNA expression reflects DNA repair, cell proliferation, metastasis, and worse survival in breast cancer.

(2022) · PubMed Central · Cited by 12

The Gut Microbiome and Metastatic Renal Cell Carcinoma

Meza, L., Feng, M., Lee, K., Sperandio, R., & Pal, S. K. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12041502 · Cited by 12

Expression of the immune checkpoint receptor TIGIT in seminoma

Hinsch, A., Blessin, N., Simon, R., Kluth, M., Fischer, K., Hube‑Magg, C., Li, W., Makrypidi‑Fraune, G., Wellge, B., Mandelkow, T., et al. (2019) · Oncology Letters · doi:10.3892/ol.2019.10428 · Cited by 12

Polyclonal Rabbit Anti-Cancer-Associated Fibroblasts Globulins Induce Cancer Cells Apoptosis and Inhibit Tumor Growth

Li, X., Huang, F., Xu, X., & Hu, S. (2018) · International Journal of Biological Sciences · doi:10.7150/ijbs.26520 · Cited by 11

Successful use of adalimumab in immune checkpoint inhibitor-associated inflammatory arthritis

Oke, A. R., Wheater, M., Karydis, I., & Wallis, D. (2018) · Rheumatology Advances in Practice · doi:10.1093/rap/rky001 · Cited by 11

CD8 T Cell–Independent Antitumor Response and Its Potential for Treatment of Malignant Gliomas

Murphy, K., & Griffith, T. (2016) · Cancers · doi:10.3390/cancers8080071 · Cited by 11

Bacterial membrane-modified cerium oxide nanoboosters enhance systemic antitumor effects of radiotherapy in metastatic triple-negative breast cancer

Chen, S.-F., Ng, P.-L., Lai, C.-W., Wang, F.-J., Wang, Y.-C., Chen, M.-H., Tung, F.-I., & Liu, T.-Y. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03187-3 · Cited by 11

Efficacy and Safety of Anti-PD1/PDL1 in Advanced Biliary Tract Cancer: A Systematic Review and Meta-Analysis

Jiang, Q., Huang, J., Zhang, B., Li, X., Chen, X., Cui, B., Li, S., & Guo, G. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.801909 · Cited by 11

Spatiotemporal analysis of tumour-infiltrating immune cells in biliary carcinogenesis

Charbel, A., Tavernar, L., Albrecht, T., Brinkmann, F., Verheij, J., Roos, E., Vogel, M. N., Köhler, B., Springfeld, C., Brobeil, A., et al. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-01933-0 · Cited by 11

A Computational Approach Identifies Immunogenic Features of Prognosis in Human Cancers

Manoharan, M., Mandloi, N., Priyadarshini, S., Patil, A., Gupta, R., Iyer, L., Gupta, R., & Chaudhuri, A. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.03017 · Cited by 10

Clinical and Biological Activity of Chemoimmunotherapy in Advanced Endometrial Adenocarcinoma: A Phase II Trial of the Big Ten Cancer Research Consortium

Barber, E. L., Chen, S., Pineda, M. J., Robertson, S. E., Hill, E. K., Teoh, D., Schilder, J., O'Shea, K. L., Kocherginsky, M., Zhang, B., et al. (2022) · Cancer Research Communications · doi:10.1158/2767-9764.crc-22-0147 · Cited by 9

Machine learning and multi-omics data reveal driver gene-based molecular subtypes in hepatocellular carcinoma for precision treatment

Wang, M., Yan, X., Dong, Y., Li, X., & Gao, B. (2024) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1012113 · Cited by 9

The occurrence of immune-related adverse events is an independent risk factor both for serum HBsAg increase and HBV reactivation in HBsAg-positive cancer patients receiving PD-1 inhibitor combinational therapy

Zeng, Y., Huang, J., Pang, J., Pan, S., Wu, Y., Jie, Y., Li, X., & Chong, Y. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1330644 · Cited by 9

Recurrent Adrenergic Stress Provokes Persistent Myocarditis in PD-1–Deficient Mice

Hayashi, T., Lim, K. R. Q., Kovacs, A., & Mann, D. L. (2023) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2023.07.012 · Cited by 8

A planar polarized MYO6-DOCK7-RAC1 axis promotes tissue fluidification in mammary epithelia

(2023) · doi:10.1016/j.celrep.2023.113001 · Cited by 8

Effects of tumor-infiltrating lymphocytes on nonresponse rate of neoadjuvant chemotherapy in patients with invasive breast cancer

Qian, X.-L., Xia, X.-Q., Li, Y.-Q., Jia, Y.-M., Sun, Y.-Y., Song, Y.-M., Xue, H.-Q., Hao, Y.-F., Wang, J., Wang, X.-Z., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-36517-2 · Cited by 8

Immunotherapeutic strategies in breast cancer: a clinical update

Zhang, J. Q., & Plitas, G. (2021) · Journal of Surgical Oncology · doi:10.1002/jso.26287 · Cited by 6

Machine learning-based somatic variant calling in cell-free DNA of metastatic breast cancer patients using large NGS panels

Jongbloed, E. M., Jansen, M. P. H. M., de Weerd, V., Helmijr, J. A., Beaufort, C. M., Reinders, M. J. T., van Marion, R., van IJcken, W. F. J., Sonke, G. S., Konings, I. R., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-37409-1 · Cited by 6

The development of a t umor‐associated autoantibodies panel to predict clinical outcomes for immune checkpoint i nhibitor‐based treatment in patients with advanced n on‐small‐cell lung cancer

Zhao, J., Wu, Y., Yue, Y., Chen, M., Xu, Y., Liu, X., Liu, X., Gao, X., Wang, H., Si, X., et al. (2023) · Thoracic Cancer · doi:10.1111/1759-7714.14772 · Cited by 6

Safety and tolerability of first‐line durvalumab with tremelimumab and chemotherapy in esophageal squamous cell carcinoma

Lee, D. H., Kim, H. R., Keam, B., Kato, K., Kuboki, Y., Gao, H., Yovine, A., Robbins, S. H., & Ahn, M. (2023) · Cancer Medicine · doi:10.1002/cam4.6260 · Cited by 6

Recruiting Immunity for the Fight against Colorectal Cancer: Current Status and Challenges

Al-Hujaily, E. M., Al-Sowayan, B. S., Alyousef, Z., Uddin, S., & Alammari, F. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232213696 · Cited by 6

Obstruction of BRAFV600E transcription by complementary PNA oligomers as a means to inhibit BRAF-mutant melanoma growth

Rothman, J. H., Surriga, O., de Stanchina, E., Vasudeva, S. D., & Schwartz, G. K. (2017) · Cancer Gene Therapy · doi:10.1038/cgt.2017.34 · Cited by 4

PathNetDRP: a novel biomarker discovery framework using pathway and protein–protein interaction networks for immune checkpoint inhibitor response prediction

Lee, D., Ahn, J., & Choi, J. (2025) · BMC Bioinformatics · doi:10.1186/s12859-025-06125-0 · Cited by 4